JP2019534684A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534684A5
JP2019534684A5 JP2019510693A JP2019510693A JP2019534684A5 JP 2019534684 A5 JP2019534684 A5 JP 2019534684A5 JP 2019510693 A JP2019510693 A JP 2019510693A JP 2019510693 A JP2019510693 A JP 2019510693A JP 2019534684 A5 JP2019534684 A5 JP 2019534684A5
Authority
JP
Japan
Prior art keywords
cell activator
nucleic acid
antibody
acid sequence
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534684A (ja
JP7043114B2 (ja
Filing date
Publication date
Priority claimed from US15/245,584 external-priority patent/US10294454B2/en
Application filed filed Critical
Publication of JP2019534684A publication Critical patent/JP2019534684A/ja
Publication of JP2019534684A5 publication Critical patent/JP2019534684A5/ja
Application granted granted Critical
Publication of JP7043114B2 publication Critical patent/JP7043114B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510693A 2016-08-24 2017-08-24 細胞を活性化させるための方法およびキット Active JP7043114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/245,584 2016-08-24
US15/245,584 US10294454B2 (en) 2016-08-24 2016-08-24 Methods and kits for cell activation
PCT/US2017/048306 WO2018039400A1 (en) 2016-08-24 2017-08-24 Methods and kits for cell activation

Publications (3)

Publication Number Publication Date
JP2019534684A JP2019534684A (ja) 2019-12-05
JP2019534684A5 true JP2019534684A5 (enExample) 2020-07-30
JP7043114B2 JP7043114B2 (ja) 2022-03-29

Family

ID=59914514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510693A Active JP7043114B2 (ja) 2016-08-24 2017-08-24 細胞を活性化させるための方法およびキット

Country Status (5)

Country Link
US (2) US10294454B2 (enExample)
EP (1) EP3504323A1 (enExample)
JP (1) JP7043114B2 (enExample)
CN (1) CN109563484A (enExample)
WO (1) WO2018039400A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294454B2 (en) * 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
GB201820444D0 (en) * 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CN110184239B (zh) * 2019-06-12 2021-04-06 蓝莲(杭州)生物科技有限公司 一种活性化t淋巴细胞培养液及其活性化t淋巴细胞的制备方法
CN116133681A (zh) * 2020-06-29 2023-05-16 加拿大干细胞技术公司 用于刺激细胞的组合物、系统和方法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
JP2618497B2 (ja) 1989-10-03 1997-06-11 鐘淵化学工業株式会社 腫瘍障害細胞誘導剤および腫瘍障害細胞誘導デバイス
US6106835A (en) 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US5872222A (en) 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
CA2065658A1 (en) 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6129916A (en) 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
WO1994012196A1 (en) 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
AU7052194A (en) 1993-06-04 1995-01-03 Regents Of The University Of Michigan, The Methods for selectively stimulating proliferation of t cells
CA2164646A1 (en) 1993-06-11 1994-12-22 Wade E. Bolton Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
EP0764203A1 (en) 1994-06-03 1997-03-26 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY Methods for selectively stimulating proliferation of t cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
DE69628154T2 (de) 1995-03-08 2004-03-18 The Scripps Research Institute, La Jolla Antigen präsentierendes system und aktivierung von t-zellen
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
JP4031033B2 (ja) 1995-05-04 2008-01-09 アメリカ合衆国 T細胞の改良トランスフェクション法
AU729406B2 (en) 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
DK0937251T3 (da) 1996-09-06 2007-02-19 Ortho Mcneil Pharm Inc Oprensning af antigenspecifikke T-celler
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7927595B1 (en) 1997-02-21 2011-04-19 The United States Of America As Represented By The Secretary Of The Navy Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
EP1017721B1 (en) 1997-09-16 2009-02-25 Oregon Health and Science University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
EP0941766B1 (en) 1998-03-12 2006-12-20 Miltenyi Biotec GmbH Micro column system for magnetic separation
GB2339782A (en) 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020051783A1 (en) 1998-06-05 2002-05-02 Savage Philip Michael Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
DE69942100D1 (de) 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
CA2406864A1 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
EP1526171A1 (en) 2000-02-24 2005-04-27 Xcyte Therapies, Inc Simultaneous stimulation and concentration of cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US6902933B2 (en) 2000-11-03 2005-06-07 Regents Of The University Of Michigan Surface transfection and expression procedure
KR20030093185A (ko) 2000-11-03 2003-12-06 리젠츠 오브 더 유니버시티 오브 미시간 표면 형질감염 및 발현 방법
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7670781B2 (en) 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
CN100379852C (zh) * 2002-02-08 2008-04-09 埃克斯西特治疗公司 用于在免疫缺陷患者体内恢复免疫响应的组合物和方法
CA2474186A1 (en) 2002-02-08 2003-08-14 Xcyte Therapies, Inc. Compositions and methods for restoring immune responsiveness in patients with immunological defects
US20040175373A1 (en) 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040151704A1 (en) 2002-06-28 2004-08-05 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CA2800113C (en) 2002-07-12 2015-02-03 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
EP1623017B1 (en) 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
WO2005049085A1 (en) 2003-11-18 2005-06-02 Valeocyte Therapies Llc Use of soluble complexes to facilitate cell activation
WO2005065121A2 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PT2573166T (pt) 2004-02-26 2016-07-07 Immunovative Therapies Ltd Métodos para preparar células-t para terapia celular
ATE449161T1 (de) 2004-03-04 2009-12-15 Leukocare Ag Leukozytenstimulations-matrix
GB2422834B8 (en) 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
KR20090060450A (ko) 2006-10-04 2009-06-12 얀센 파마슈티카 엔.브이. 불활성화 인공 항원 제시 세포의 제조 및 세포 치료법에서 이들의 용도
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
US20100143905A1 (en) 2007-03-29 2010-06-10 Lane Michael J Methods and compositions for multivalent binding and methods for manufacture of rapid diagnostic tests
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
WO2009117616A2 (en) 2008-03-19 2009-09-24 Yale University Carbon nanotube compositions and methods of use thereof
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
WO2011050000A2 (en) 2009-10-20 2011-04-28 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
US8945509B2 (en) 2010-08-20 2015-02-03 Life Technologies Corporation Magnetic beads having surface glycoconjugates and use thereof
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
EP3418295B1 (en) 2011-07-18 2020-09-02 IBA GmbH Method of reversibly staining a target cell
US8834889B2 (en) 2011-08-29 2014-09-16 National Tsing Hua University Antigen presenting composition and use thereof
CA2858115A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
WO2013109568A1 (en) 2012-01-17 2013-07-25 Croda, Inc. Seal swell additive
AU2013224027B2 (en) 2012-02-23 2019-01-24 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
CN105073770B (zh) 2012-11-16 2019-08-06 Iba股份有限公司 链霉亲和素突变蛋白及其使用方法
WO2014127220A1 (en) 2013-02-15 2014-08-21 The Johns Hopkins University Antigen-specific t cell redirectors
JP6501270B2 (ja) 2013-03-14 2019-04-17 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 標的化剤抗体抱合体およびその使用
KR102164405B1 (ko) 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
WO2014209868A1 (en) 2013-06-24 2014-12-31 Neximmune Compositions and methods for immunotherapy
EP2824112B1 (en) * 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
JP5799058B2 (ja) 2013-07-30 2015-10-21 三桜工業株式会社 負圧ポンプ及びシリンダヘッドカバー
JP6696969B2 (ja) 2014-04-16 2020-05-20 ユノ・セラピューティクス・ゲーエムベーハーJuno Therapeutics Gmbh 細胞の集団を拡大する方法、キット、及び装置
CA2996848C (en) * 2014-09-04 2021-01-05 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Similar Documents

Publication Publication Date Title
JP2019534684A5 (enExample)
JP2019528760A5 (enExample)
JP2020537540A5 (enExample)
US12180546B2 (en) Methods for identifying and modulating co-occurant cellular phenotypes
Liu et al. Self‐Assembled Functional DNA Superstructures as High‐Density and Versatile Recognition Elements for Printed Paper Sensors
JP2018508198A5 (enExample)
JP2017513524A5 (enExample)
US20230183786A1 (en) Methods for identifying and modulating co-occurant cellular phenotypes
JP2012515548A5 (enExample)
JP2014501518A5 (enExample)
WO2010029317A8 (en) Treating inflammatory conditions
JP2018514576A5 (enExample)
JP2016539641A5 (enExample)
Rossi et al. Detecting associations between ciliated protists and prokaryotes with culture-independent single-cell microbiomics: a proof-of-concept study
JP2014521316A5 (enExample)
EP4591882A3 (en) Ex vivo gamma delta t cell populations
JP2017522323A5 (enExample)
WO2017189631A3 (en) Methods of identifying target binding ligands from tagged combinatorial libraries
AR048614A1 (es) Metodos para transformacion de alta eficiencia y regeneracion de cultivos de plantas en suspension
WO2011153103A3 (en) Ideotypically modulated pharmacoeffectors for selective cell treatment
WO2016112882A3 (en) Macromolecular conjugates for isolation, immobilization and visualization of proteins
WO2015126976A3 (en) Methods and systems for rapid detection of microorganisms using free antibodies
GB201118030D0 (en) Nucleic acid amplification technology
Kreitzer HUMPHREY GILLET: Signatory of A Testimony to Truth (1659)
RU2024117058A (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор